DBM-819
DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H+/K+-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 331686-58-9
- Formel: C23H27N3O2
- Molecular Weight:377.48
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Chemical Information
-
CAS. Nr. 331686-58-9
-
Molecular Weight 377.48
-
Formel C23H27N3O2
-
SMILES
OCCCNC1=C(CCN2C3=CC=C(C=C3C)OC)C2=C(C=CC=C4C)C4=N1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Choi SJ, et al. In vitro metabolism of a new H(+)/K(+) ATPase inhibitor DBM-819 in liver microsomes using HPLC and electrospray mass spectrometry. Biomed Chromatogr. 2001 Dec;15(8):503-6. [Content Brief]
[2]. Kim EJ, et al. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect. Biopharm Drug Dispos. 2001 Apr;22(3):119-28. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
DBM-819 Related Classifications
HY-126751 Related Classifications
Powered by Bioz